Catheter-related bloodstream infection (CRBSI) is a major complication after CVCs insertion. is associated with significant morbidity, mortality, and additional medical costs. Many lock solutions for CRBSI have been evaluated. However, using traditional pairwise meta-analyses to summarize the evidence does not allow the inclusion of data from treatments that have not been compared head to head, which could impact the precision of pooled estimates in a metaanalysis. Therefore, we evaluated the efficacy and safety with different lock solutions for 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y CRBSI by network meta-analysis.
There are several systematic reviews that focus on different catheter lock solutions for CRBSI in CVC patients [13] [14] [15] [16] . However, the comparative effectiveness of all available lock solutions has never been examined. Traditional systematic reviews cannot compare multiple treatments simultaneously. Network meta-analysis can compare all available treatments in one synthesis even if the treatments have not been investigated directly in a RCT.
Hence, this protocol describes the methods for a network meta-analysis to assess which lock solution (or their combination) is most likely to be effective for patients with CVC. We will estimate the treatment effects among direct and indirect comparisons, and generate a ranking according to all lock solutions efficacy and safety outcomes.
METHODS AND DESIGN
This protocol will design based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Protocols 17 and Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for NMA checklist for reporting systematic review protocols and NMA [18] [19] . This review was registered in the International Prospective Register of Systematic Reviews (PROSPERO: CRD42019121089).
Patient and Public Involvement statement
As the present meta-analysis is performed based on previous published studies, thus no Patient and Public Involvement are required.
Eligibility criteria
The eligibility criteria are pre-specified according to the PICO(S) criteria.
Types of participants
The participants must be using tunnelled or non-tunnelled CVC as vascular access in the vein for ≥48 hours. Regardless of the cause and duration of use of the catheter. Patients with artery catheter or pacing wires were excluded.
Types of interventions
RCTs of antimicrobial lock solution used to prevent CRBSI will be included, regardless of whether the antimicrobials were tested between themselves (head-to-head) or control intervention such as heparin. For antimicrobials, antibiotic, citrate, taurolidine an alcohol will be included regardless of their concentration. The anticoagulants (eg, heparin, citrate or EDTA) could be given in all antimicrobial lock solution. The comparator can be placebo, heparin or a different antimicrobial lock solution. Comparing interventions of the same lock solution with different concentration is beyond the scope of this study. For example, the treatment group is the heparin 1,000 IU/ml while the control group is the heparin 5,000 IU/ml. This study will be excluded.
We included all randomized trials that met the above inclusion criteria and included at least one of the following outcomes and a control group (indirect evidence) or at least two outcomes (direct evidence).
Types of outcome
Included studies must report CRBSI as one of the endpoints (defined below). ► Primary outcome: CRBSI: The definitions of CRBSI according to the Infectious Diseases Society of America recommendations 20 . A definite CRBSI is a bacteremia in a patient who has an intravascular device and >1 positive blood culture with a recognized pathogen or common commensal, with F o r p e e r r e v i e w o n l y confirmation of infection by isolation of the same organism following culture of catheter tip, or a differential time to positivity for centrally and peripherally drawn blood cultures of ≥2 h. ► Secondary outcomes: Catheter related thrombosis (CRT): According to doppler ultrasound. CVC-related thrombosis is diagnosed in case of noncompressibility of the vein, visualization of an echogenic intraluminal mass, and absence of respiratory variation, or monophasic flow within 30 days after insertion of the CVC and within 24 h after removal of the CVC 21 . In our NMA, the inability to use the catheter at a blood flow >200 mL/min despite additional flushing and intraluminal thrombolysis was used for the definition of thrombosis 22 . Exit site infection: According to the Centers for Disease Control (CDC, Atlanta, GA, USA), the exit site infection is the appearance of erythema, tenderness and/or induration within 2 cm of the dialysis catheter exit site with or without purulent exudates or microbiological exit site infection where the exudates lead to microorganism's growth in the culture 23 . Study authors will use a variety of definitions for bleeding and for CRBSI. If several definitions of CRBSI are presented in the same study, our preferred definition will be according to the Infectious Diseases Society of America recommendations 20 . The secondary outcomes will be defined according to per study author definition.
Types of studies
Eligible studies are RCTs assessing the effect of lock solutions in prevention of CRBSI.
Search strategy
We will search PubMed, the Cochrane Library, Embase and Web of Science from inception to January 2019. We will create the search strategy to combine relevant Medical Subject Headings (MeSH) and keywords with synonyms and names of generic and brand names of all catheter lock solutions. The search strategy will be developed by JHT, who has more than 10 years of experience as an information specialist. We will also track the references in the included articles and relevant systematic reviews/meta-analyses in order to identify additional relevant studies. Meanwhile, we will weekly re-search above electronic databases to identify any new published articles until the submission of the present study. Non-English language studies and duplicate publications of original research will be excluded. We will also exclude ongoing RCTs without extractable data.
Study selection
Literature search records will be imported into EndNoteX8 literature management software (Thomson Reuters, New York, NY, USA). Two researchers (F-PD & J-HT) will independently review the title and abstract of the studies and exclude those that clearly did not meet the inclusion criteria. Then the remaining studies will identify by reviewing the full text according to prespecified inclusion criteria. Any disagreements will be resolved by discussion or through the third reviewer (H-JL). The selection process is shown in supplementary figure 1.
Data extraction
Data will independently be extracted by two authors (F-PD & J-HT) from each included RCT according to a pre-designed Excel spreadsheet created in Microsoft Excel 2016 (Microsoft Corp, Redmond, WA, USA). The study data will include study and publication details, participants (in supplementary table 1) . If disagreement persists, a third reviewer (H-JL) will take the decision.
Risk of bias assessment
The methodological risk of bias of included RCTs will be assessed according to the Cochrane Collaboration Risk of Bias Tool 24 , including the method of random sequence generation (selection bias), allocation concealment, blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias) and other bias. Those items will be evaluated as being high, low or unclear risk of bias. Any disagreements will be resolved through discussion and reached a consensus with the third reviewer (H-JL).
Data synthesis and statistical methods
We plan this NMA to assess which lock solution for CRBSI is most effective. We will construct the networks for the primary and (each) secondary outcome separately.
Bayesian NMA
Bayesian network meta-analysis will be performed in WinBUGS 1. Model fit will be determined based on the deviance information criteria (DIC) for each outcome measure. It is best to choose the lowest model of DIC (differences > 3 are considered meaningful) 25 . Two Markov chains will run simultaneously with different arbitrarily chosen initial values. We will generate the simulations for each chain if the convergence will be found to be adequate. Then, these simulations will be discarded as 'burn-in'. To ensure convergence, the model convergence will be assessed by trace plots 26 .
Methods for indirect and direct comparisons
We will conduct the separate pairwise meta-analyses using the random-effects model to compare all the interventions with available direct evidence. Dichotomous data will be determined by using odds ratio (OR) with 95% confidence interval (CI). Continuous outcomes will be analysed using weighted mean differences or standardized mean differences if different measurement scales are used. To present indirect comparisons of catheter lock solution, a network diagram will be drawn. Trials will be excluded if they are not connected by any treatments. The common comparator will be heparin as it is the current standard care 27 . In this network plot, nodes represent different interventions and edges represent the head-to-head comparisons between interventions. The size of the node reflects the sample size of the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y intervention, and the thickness of the edge reflects the number of included trials.
Dealing with missing data
We will attempt to obtain missing data from authors of the included randomised trials by mail.
We will explore the potential impact of the missing data by the sensitivity analyses and record the number of the 'loss to follow-up'. We will also extract data from studies that report outcomes using the intention-to-treat.
Treatment ranking
To estimate the percentage of efficacy of each catheter lock solution for being at each possible rank, the surface under the cumulative ranking curve (SUCRA) which are expressed as percentages will be used. SUCRA value is 100% for the best treatment and 0% for the worst treatment. The higher the SUCRA score, the more efficacious the treatment is expected to be [28] [29] .
Assessment of heterogeneity
Clinical and methodological heterogeneity will be assessed by carefully examining the study population characteristics, interventions and outcome of included trials and comparing fit of the fixed and random effect models. The statistical heterogeneity within each pairwise comparison will be measured by using the I 2 index 30 . Substantial heterogeneity will be considered where I 2 is >50%. If considerable heterogeneity is found, network meta-regression or subgroup analysis will be used to explore possible sources of heterogeneity. Subgroup analysis and sensitivity analysis Subgroup analyses and network meta-regression were planned to perform according to type of catheter, catheter insertion site, catheter days/lock time, age and study quality. We will perform sensitivity analyses of the outcomes to determine the sensitivity of results to changes in the original assumptions by excluding trials with a high risk of bias in seven items, and excluding trials where the criterion of CRBSI diagnosis does not meet the above defined.
Assessment of inconsistency
Inconsistency means the presence of disagreement between the different sources of evidence 31 .
We will evaluate the inconsistency between direct and indirect evidence when a loop is formed between treatments. The node-split method will be used to explore where in the network the inconsistency is 32 . We will attempt to identify inconsistencies jointly from all possible sources in the network using the design-by-treatment interaction model and I 2 index, when possible [33] [34] .
Public bias
When each direct treatment comparison and outcome contains sufficient number of studies (at least 10 studies), we will assess the possibility of public bias by visually examining the asymmetry of funnel plots and Egger's regression test 24 . We will use comparison-adjusted funnel plot 35 to explore the potential small-study effects in the network and use contourenhanced funnel plots to examine whether funnel plot asymmetry is caused by publication bias.
If the publication bias is found, we will fit a selection model to obtain relative effects 'adjusted' for the impact of publication bias 36 .
QUALITY OF THE EVIDENCE
We will propose the following GRADE four-step approach 37 to assess the quality of treatment 4 . Rate the quality of each NMA effect estimate. According to the GRADE group, we will classify the quality of evidence into four levels: high quality, moderate quality, low quality and very low quality. Evaluating the quality of evidence from a network meta-analysis. PloS one, 9(7), e99682. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
3 Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
3
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
3-4
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
2-3
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
4
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). 
Abstract
Introduction: Catheter-related bloodstream infection (CRBSI) is a major complication after central venous catheter (CVC) insertion, which is associated with significant morbidity, mortality, and additional medical costs. Many lock solutions for CRBSI have been evaluated. However, using traditional pairwise meta-analyses to summarise the evidence does not allow the inclusion of data from treatments that have not been compared head to head, which could impact the precision of pooled estimates in a meta-analysis. Therefore, we evaluated the efficacy and safety of the different lock solutions for CRBSI through a network meta-analysis.
Methods and analysis:
The primary outcome of this network meta-analysis is the CRBSI. The secondary outcomes are exit-site infection and catheter-related thrombosis (CRT). We will search the PubMed, Embase, Web of Science, and the Cochrane Library databases for recent relevant meta-analysis and their reference lists to include randomised controlled trials (RCTs) that compared lock solutions for CRBSI prevention. Two individuals will independently extract data from each included RCT according to a pre-designed Excel spreadsheet and will assess the methodological quality using the Cochrane risk of bias tool. We will analyse the data using WinBUGS (V.1.4.3) and Stata (V.15.0). We will also estimate the pooled direct and indirect effects for all lock solutions using the network meta-analysis.
Ethics and dissemination:
As the present meta-analysis is performed based on previous published studies, no ethical approval and patient safety considerations are required. This study commenced on18 January 2019, and its expected completion date is 1 December 2019. We will disseminate the results of our network meta-analysis through an international peer-reviewed journal. Strengths and limitations of the study: ► This review is anticipated to be the first network meta-analysis to addresses the important concern of which lock solution is most effective for CRBSI. ► This network meta-analysis has a comprehensive literature search strategy involving restriction of studies to randomised controlled trials, duplicate assessment of eligibility and risk of bias, and data abstraction. Meanwhile, we will use the Grade of Recommendations Assessment, Development and Evaluation to assess the quality of treatment effect estimates from the network meta-analysis. ► Only included studies written in English may lead to publication bias. Therefore, the prevention of CRBSI is one of the major challenges in the routine care of CVC patients. Consequently, several measures have been developed to prevent CRBSI, including antimicrobial dressings, catheter impregnation, antiseptic agents, and education and training of medical workers. [4] [5] [6] Recently, the use of catheter lock solutions has been associated with improved clinical outcomes and reduction of CRBSI after CVC insertion. [7] [8] The catheter lock solution is the injection of antimicrobials, wherein antibiofilms are instilled in the lumen of the CVC to eradicate organisms and prevent biofilm formation, thereby eliminating the source of CRBSI. [9] [10] [11] At present, the most common lock solution is the use of heparin and saline to flush the lumen of the catheter. [12] There are several systematic reviews that focused on different catheter lock solutions for CRBSI in CVC patients. [13] [14] [15] [16] A previous meta-analysis [13] included 6 RCTs and 431 patients and showed that taurolidine reduced the incidence of CRBSI without obvious adverse effects and bacterial; however, it did not conclude whether it is associated with a higher risk for CRT compared with heparin. The studies by reported that the ethanol lock is effective in reducing the incidence of CRBSI in haemodialysis and paediatric patients compared to heparin. The study by Zacharioudakis et al. [16] study included 23 RCTs and 2896 patients who were predominantly adult patients undergoing haemodialysis (16/23 studies), and they suggested that antimicrobial lock solutions led to a 69% reduction in the CRBSI rate and 32% reduction in the rate of exit-site infections compared with heparin.
PROSPERO registration number: CRD42019121089.
However, the comparative effectiveness of all available lock solutions has never been examined. Traditional systematic reviews cannot compare multiple treatments simultaneously. A network meta-analysis (NMA) can compare all available treatments in one synthesis even if the treatments have not been investigated directly in a RCT.
Hence, this protocol describes the methods for an NMA to assess which lock solution (or their combination) is most likely to be effective for patients with CVC. We will also estimate the treatment effects through direct and indirect comparisons, and generate a ranking according to the efficacy and safety outcomes of all solutions.
METHODS AND ANALYSIS
This protocol follows the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P) [17] and Preferred Reporting Items for Systematic Reviews and MetaAnalyses extension for NMA checklist for reporting systematic review protocols and NMA. [18] [19] This review was registered in the International Prospective Register of Systematic Reviews (PROSPERO: CRD42019121089)."
Eligibility criteria
Types of participants
All patients who underwent CVC insertion will be included. We will not impose an age restriction. Studies will be included if they use antimicrobial lock solutions for CRBSI. The participants must be using a tunnelled or non-tunnelled CVC as venous access for ≥48 hours. Patients with artery catheter or pacing wires were excluded regardless of the cause and duration of catheter use.
Types of interventions
RCTs of antimicrobial lock solutions used to prevent CRBSI will be included, regardless of whether the antimicrobials were tested between themselves (head-to-head) or against placebo/control intervention such as heparin. For antimicrobials, antibiotics, citrate, taurolidine, and alcohol will be included regardless of their concentration. The anticoagulants (e.g., heparin, citrate, or EDTA (Minocycline-EDTA Lock Solution)) could be given in all antimicrobial lock solutions. The comparator can be placebo, heparin, or a different catheter lock solution. Comparing interventions of the same lock solution with different concentrations is beyond the scope of this study. For example, if the treatment group was administered 1,000-IU/ml heparin, whereas the control group was administered 5,000-IU/ml heparin, this study will be excluded.
We included all RCTs that met the abovementioned inclusion criteria and included a control group (indirect evidence) or at least two interventions (direct evidence).
Types of outcome
Included studies must report CRBSI as one of the endpoints (defined below). Primary outcome: CRBSI is defined according to the Infectious Diseases Society of America recommendations.
[20] A definite CRBSI is diagnosed in a patient with bacteraemia who has an intravascular device and >1 positive blood culture with a recognised pathogen or common commensal, with confirmation of infection by isolation of the same organism following culture of the catheter tip, or a differential time to positivity for centrally and peripherally drawn blood cultures of ≥2 h. Secondary outcomes Catheter-related thrombosis (CRT): According to the Doppler ultrasound. CVC-related thrombosis is diagnosed in case of noncompressibility of the vein, visualization of an echogenic intraluminal mass, and absence of respiratory variation or monophasic flow within 30 days after insertion of the CVC and within 24 h after removal of the CVC. [21] In our NMA, the inability to use the catheter at a blood flow of >200 mL/min despite additional flushing and intraluminal thrombolysis was used for the definition of thrombosis. [22] Exit-site infection: According to the Centers for Disease Control (CDC, Atlanta, GA, USA), the exit-site infection is the appearance of erythema, tenderness, and/or induration within 2 cm of the dialysis catheter exit site with or without purulent exudates; microbiological exit-site infection is characterised by presence of exudates leading to microorganism's growth in the culture. [23] The study authors will use a variety of definitions for bleeding and CRBSI. If several definitions of CRBSI are presented in the same study, our preferred definition will be according to the Infectious Diseases Society of America recommendations.
[20] The secondary outcomes will be defined according to the author definition of each study.
Types of studies
Eligible studies are RCTs assessing the effect of lock solutions in the prevention of CRBSI.
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Search strategy
We will search PubMed, Embase, the Cochrane Library, and Web of Science from inception until January 2019. We will create the search strategy to combine relevant Medical Subject Headings (MeSH) and keywords with synonyms and names of generic and brand names of all catheter lock solutions. The search strategy will be developed by JHT, who has more than 10 years of experience as an information specialist. We have provided a draft of a full electronic search strategy for PubMed in supplementary file named "Search Strategy". We will also track the references in the included articles and relevant systematic reviews/meta-analyses to identify additional relevant studies. Meanwhile, we will perform weekly research in the abovementioned electronic databases to identify any newly published articles until the submission of the present study. Non-English studies and duplicate publications of original research will be excluded. We will also exclude ongoing RCTs without extractable data.
Study selection
Literature search records will be imported into EndNoteX8 literature management software (Thomson Reuters, New York, NY, USA). Two researchers (F-PD and J-HT) will independently review the title and abstract of the studies and exclude those that clearly did not meet the inclusion criteria. Then, the remaining studies will be identified by reviewing the full text according to the prespecified inclusion criteria. Any disagreements will be resolved by discussion or through a third reviewer (H-JL).
Data extraction
Data will be independently extracted by two authors (F-PD and J-HT) from each included RCT according to a pre-designed Excel spreadsheet created in Microsoft Excel 2016 (Microsoft Corp, Redmond, WA, USA). The study data will include study and publication details, participants and intervention characteristics as well as outcome. If disagreement persists, a third reviewer (H-JL) will make the decision.
Risk of bias assessment
The methodological risk of bias of included RCTs will be assessed according to the Cochrane Collaboration Risk of Bias Tool [24] including the method of random sequence generation (selection bias), allocation concealment, blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other biases. These items will be evaluated as having high, low, or unclear risk of bias. Any disagreements will be resolved through a discussion and reaching a consensus with the third reviewer (H-JL).
Data synthesis and statistical methods
We planned this NMA to assess which lock solution for CRBSI is most effective. We will construct the networks for the primary and secondary outcomes separately. Model fit will be determined based on the deviance information criteria (DIC) for each outcome measure. It is best to choose the lowest model of DIC (differences > 3 are considered meaningful). [25] Two Markov chains will run simultaneously with different arbitrarily chosen initial values. We will generate the simulations for each chain if the convergence will be found to be adequate. Then, these simulations will be discarded as 'burn-in'. To ensure convergence, the model convergence will be assessed by trace plots. [26] 
Methods for indirect and direct comparisons
We will conduct the separate pairwise meta-analyses using the random-effects model to compare all the interventions with available direct evidence. Dichotomous data will be determined by using odds ratio (OR) with 95% confidence interval (CI). Continuous outcomes will be analysed using weighted mean differences or standardised mean differences if different measurement scales are used. To present indirect comparisons of the catheter lock solutions, a network diagram will be drawn. Trials will be excluded if they are not connected by any treatments. The common comparator will be heparin as it is the current standard of care. [27] In this network plot, nodes represent different interventions and edges represent the head-to-head comparisons between interventions. The size of the node reflects the sample size of the intervention, and the thickness of the edge reflects the number of included trials.
Dealing with missing data
We will attempt to obtain missing data from authors of the included RCTs by mail. We will explore the potential impact of the missing data by performing a sensitivity analyses and record the number of patients 'loss to follow-up'. We will also extract data from studies that report outcomes using the intention-to-treat.
Treatment ranking
To estimate the percentage of efficacy of each catheter lock solution for being at each possible rank, the surface under the cumulative ranking curve (SUCRA) values, which are expressed as percentages will be used. The SUCRA value is 100% for the best treatment and 0% for the worst treatment. The higher the SUCRA score, the more efficacious the treatment is expected to be. [28] [29] Assessment of heterogeneity Clinical and methodological heterogeneity will be assessed by carefully examining the study population characteristics, interventions, and outcomes of the included trials and comparing fit of the fixed and random effect models. The statistical heterogeneity within each pairwise comparison will be measured by using the I 2 index. [30] Substantial heterogeneity will be considered where I 2 is >50%. If considerable heterogeneity is found, network meta-regression or subgroup analysis will be used to explore possible sources of heterogeneity. Subgroup and sensitivity analyses Subgroup analyses and network meta-regression were planned to perform according to the type of catheter, catheter insertion site, catheter days/lock time, age, and study quality. We will perform sensitivity analyses of the outcomes to determine the sensitivity of results to changes in the original assumptions by excluding trials with a high risk of bias in seven items, and excluding trials where the criterion of CRBSI diagnosis does not meet the above mentioned definition.
Assessment of inconsistency
Inconsistency means the presence of disagreement between the different sources of evidence. [31] We will evaluate the inconsistency between direct and indirect evidence when a loop is formed between treatments. The node-split method will be used to explore where the inconsistency is found. [32] We will attempt to identify inconsistencies jointly from all possible sources in the network using the design-by-treatment interaction model and I 2 index, when possible. [33] [34] 
Publication bias
When each direct treatment comparison and outcome contains a sufficient number of studies (at least 10 studies), we will assess the possibility of publication bias by visually examining the asymmetry of funnel plots and Egger's regression test. [24] We will use a comparison-adjusted funnel plot to explore the potential small-study effects in the network and use contour-enhanced funnel plots to examine whether the funnel plot asymmetry is caused by a publication bias. [35] If the publication bias is found, we will fit a selection model to obtain relative effects 'adjusted' for the impact of publication bias.
[36] QUALITY OF THE EVIDENCE We will propose the following GRADE four-step approach [37] to assess the quality of treatment effect estimates from NMA: 1. present direct and indirect treatment estimates for each comparison of the evidence network; 2. rate the quality of each direct and indirect effect estimate; 3. present the NMA estimate for each comparison of the evidence network; and 4. rate the quality of each NMA effect estimate. According to the GRADE group, we will classify the quality of evidence into the following four levels: high quality, moderate quality, low quality, and very low quality.
Potential limitations of the planned work
Some potential limitations of this NMA are predictable. First, excluding non-English studies may cause a publication bias. Second, we will only include RCT publications to support our intention to include only high-quality evidence, which indicate that there is a possibility that the study population will not be representative of the overall population. Besides, we only included patients with CRBSI defined according to the Infectious Diseases Society of America recommendations, which will increase the risk of bias and heterogeneity. Finally, if the number of included studies is small, our ability to explore heterogeneity, conduct a meta regression analysis and even perform NMA is limited. Meanwhile, if the degree of clinical heterogeneity is substantial, the internal validity will be threatened.
Ethics and dissemination
Given that the present meta-analysis is performed based on previous published studies, no ethical approval and patient safety considerations are required. This study commenced at 18 January 2019, and its expected completion date is 1 December 2019. We will disseminate the results of our network meta-analysis through an international peer-reviewed journal.
Contributors
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Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review Page 6
Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)
Page 6
Data collection process 11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators Page 6
Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications Page 5-6
Outcomes and prioritization 13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale Page 5-6
Risk of bias in individual studies 14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46 
